粉作为可设计的口服药物输送平台:从结构调节到炎症性肠病中的应用
Mengyuan Qin1, Feng Jiang1, Yan Hong2
1State Key Laboratory of Food Science and Resources, Jiangnan University, Wuxi, 214122, Jiangsu Province, China.
Carbohydrate polymers
|March 14, 2026
概括
本综述探讨了针对性炎症性肠病 (IBD) 治疗的基于粉的载体. 这些智能口服输送系统旨在精确地在结肠中释放药物,提高疗效并减少副作用.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 药物输送系统 药物输送系统
背景情况:
- 炎症性肠病 (IBD) 管理受到局部特定药物输送到结肠的挑战所限制.
- 传统的口服治疗面临的问题是放出目标外,生物可用性差,以及全身副作用.
研究的目的:
- 审查粉作为工程智能结肠向药物输送载体IBD的基础材料.
- 检查粉的特性如何使胃肠导航和向释放的输送系统的合理设计成为可能.
主要方法:
- 对基于粉的载体进行化学,物理和酶修改策略的审查.
- 对微环境响应性行为和主动准的粉载体设计的分析.
- 基于粉的口服输送系统中结构与功能关系的检查.
主要成果:
- 粉的层次结构和可调化学结构允许智能载体设计.
- 修改策略赋予了粉载体的响应能力和积极准能力.
- 设计的粉系统显示出在IBD中具有多机制治疗效果的潜力.
结论:
- 粉是一种多功能生物材料,用于开发下一代IBD口服输送平台.
- 这些平台通过加强上皮屏障,恢复微生物平衡,并重新校准免疫反应,提供精确的局部干预.
- 结构对功能的方法为基于粉的先进IBD疗法提供了战略理由.
相关概念视频
Oral Drug Delivery Systems: Introduction
153
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
153
Oral Drug Delivery Systems: Delayed-Release Systems
96
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
96
Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
296
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
296
Drug Delivery Systems: Different Types
166
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
166
Site-Targeted Drug Delivery Systems: Polymeric Carriers
79
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
79


